Adherence to folic acid supplementation among children with sickle cell disease diagnosed through the newborn screening program: associated factors.
DOI:
https://doi.org/10.33448/rsd-v11i3.26566Keywords:
Anemia, Sickle Cell; Hemoglobin SC; Folic Acid; Medication Adherence.Abstract
Introduction: Folic acid is used as a prophylactic therapy in haemolytic anaemia. Low adherence to folic acid in children with sickle cell disease contributes to the emergence of complications and worsening of health, and thus an increase in care costs. Objective: To analyse medication adherence to folic acid in children with sickle cell disease, haemoglobin SS (HbSS) or SC (HbSC), diagnosed by neonatal screening. Methods: Cross-sectional study, by measurements of serum folate levels in children and application of the Morisky-Green Test (MGT) and Brief Medication Questionnaire (BMQ) to caregivers. Results: There were 34.0% and 40.4% of “adherents” for MGT and BMQ. Elevated serum folate was found in 78.7% of the participants, and none of them had deficiency. Pharmaceutical form (p=0.719), age group (p=0.875), income (p=0.944) and caregiver’s education (p=0.070) were not associated factors to adherence. HbSS patients record more than four times the adherence of HbSC (48.3% vs. 11.1%; p=0.012). Difficulty of access to the medication and interruption/lagging of treatment were the main contributors to non-adherence. Conclusion: There was a contrast between the adherence reported by the questionnaires and the high serum folate levels.
References
Adriano L.S., Fonteles M.M.F., Azevedo M.F.M., Beserra M.P.P., Romero N.R. (2017). Medication adherence in patients with juvenile idiopathic arthritis. Rev Bras Reumatol., 57(1):23-29.
Alves M.A., Souza A.M., Barufaldi L.A., Tavares B.M., Bloch K.V., Vasconcelos F.A.G. (2019). Dietary patterns of Brazilian adolescents according to geographic region: an analysis of the Study of Cardiovascular Risk in Adolescents (ERICA). Cad Saude Publica, 35(6):e00153818.
Amorim T., Pimentel H., Fontes M.I.M.M., Purificação A., Lessa P., Boa-Sorte N. (2010). Avaliação do programa de triagem neonatal da Bahia entre 2007 e 2009 - As lições da doença falciforme. Gaz. méd. Bahia, 80(3):10-13.
Azzam M. & Attalla S. (2019). Serum Folate Levels in Patients with Chronic Hemolytic Anemia on Regular Folic Acid Supplementation Before and After Dose Modification. Indian Pediatr., 56(10):845-848.
Bandeira F.M.G.C., Bezerra M.A.C., Santos M.N.N., Gomes Y.M., Araújo A.S., Abath F.G.C. (2007). Importância dos programas de triagem para o gene da hemoglobina S. Rev Bras Hematol Hemoter., 29(2):179-84.
Ben A.J. (2011). Confiabilidade e Análise de Desempenho de Dois Questionários de Avaliação da Adesão ao Tratamento Anti-hipertensivo: Teste de Morisky-Green e Brief Medication Questionnaire [dissertação]. Porto Alegre (RS): Universidade Federal do Rio Grande do Sul; 2011.
Ben A.J., Neumann C.R., Mengue S.S. (2012). The Brief Medication Questionnaire and Morisky-Green test to evaluate medication adherence. Rev Saude Publica, 46(2):279-289.
Beckman Coulter Inc. Access® Immunoassay Systems – Folate. 2005. [acessado 2019 jun 09]. http://www.biosystemsne.com.br/files/product/4b3390f9ec51a.511a14208.pdf.
Bitarães E.L., Oliveira B.M., Viana M.B. (2008). Adesão à antibioticoterapia profilática em crianças com anemia falciforme: um estudo prospectivo. J Pediatr,84(4):316-22.
Braga J.A.P. (2007). Medidas gerais no tratamento das doenças falciformes. Rev Bras Hematol Hemoter., 29(3):233-8.
Brasil. (2005). Organização Pan Americana da Saúde (OPAS). Avaliação da assistência farmacêutica no Brasil: estrutura, processo e resultados. Brasília: OPAS.
Brasil. (2009). Portaria Nº 1.793, de 11 de agosto de 2009. Institui a Comissão Interinstitucional para Implementação, Acompanhamento e Monitoramento das Ações de Fortificação das Farinhas de Trigo, de Milho e de seus Subprodutos. Diário Oficial da União 2009; 11 ago.
Brasil. (2012). Ministério da Saúde (MS). Doença falciforme: condutas básicas para tratamento. Brasília: Ministério da Saúde.
Brasil. (2016). Ministério da Saúde (MS). CONITEC – Comissão Nacional de Incorporação de Tecnologias em Saúde. Protocolo Clínico e Diretrizes Terapêuticas de Doença Falciforme. Brasília: Ministério da Saúde.
Bugni V.M., Ozaki L.S., Okamoto K.Y., Barbosa C.M., Hilário M.O., Len C.A., Terreri M.A. (2012). Factors associated with adherence to treatment in children and adolescents with chronic rheumatic diseases. J Pediatr (Rio J), 88(6):483-8.
Caldas P., Boa-Sorte N., Amorim T., Freitas M., Ribeiro R., Fonseca SFd. (2010). Eventos Clínicos e Fatores Associados em uma coorte de crianças com Doença Falciforme. Gaz. méd. Bahia, 80(3):14-19.
Cançado R.D. & Jesus J.A. (2007). A doença falciforme no Brasil. Rev Bras Hematol Hemoter., 29(3):204-206.
Dixit R., Nettem S., Madan S.S., Soe H.H.K., Abas A.B., Vance L.D., Stover P.J (2018). Folate supplementation in people with sickle cell disease. Cochrane Database Syst Rev.,3(3):CD011130.
Leal K.K., Schneider B.C., França G.V., Gigante D.P., dos Santos I., Assunção M.C. (2015). Diet quality of preschool children aged 2 to 5 years living in the urban area of Pelotas, Brazil. Rev Paul Pediatr., 33(3):311-318.
Liberato S.M.D., Souza A.J.G., Gomes A.T.L., Medeiros L.P., Costa I.K.F., Torres G.V. (2014). Relação entre adesão ao tratamento e qualidade de vida: revisão integrativa da literatura. Rev Eletr Enferm.,16(1):191-198.
Nascimento R.C.R.M., Álvares J., Guerra A.A., Gomes I.C., Costa E.A., Leite S.N., Costa K.S., Soeiro O.M., Guibu I.A., Karnikowski M.G.O., Acurcio F.A. (2017) Availability of essential medicines in primary health care of the Brazilian Unified Health System. Rev Saude Publica, 51(2):10s.
Nguyen G.T., Lewis A., Goldener C., Reed B., Dulman R.Y., Yang E. (2017). Discontinuation of Folic Acid Supplementation in Young Patients With Sickle Cell. Anemia. J Pediatr Hematol Oncol.,39(6):470-472.
Obreli-Neto P.R., Baldoni A.O.B., Guidoni C.M., Bergamini D., Hernandes K.C., da Luz R.T, da Silva F.B., de Oliveira e Silva R., Pereira L.R.L., Cuman R.K.N. (2012). Métodos de avaliação de adesão à farmacoterapia. Rev Bras Farm, 93(4):403-410.
Patel N.G., Lindsey T., Strunk R.C., DeBaun M.R. (2010). Prevalence of daily medication adherence among children with sickle cell disease: a 1-year retrospective cohort analysis. Pediatr Blood Cancer, 55(3):554-556.
Piel F.B., Patil A.P., Howes R.E., Nyangiri O.A., Gething P.W., Dewi M., Temperley W.H., Williams T.N., Weatherall D.J., Hay S.I. (2013). Global epidemiology of sickle haemoglobin in neonates: a contemporary geostatistical model-based map and population estimates. Lancet, 381(9861):142-51.
Remondi F.A., Cabrera M.A., Souza R.K. (2014). Non-adherence to continuous treatment and associated factors: prevalence and determinants in adults 40 years and older. Cad Saude Publica, 30(1):126-136.
Steiner S.A., Torres M.R.F., Penna F.J., Melo M.C.B. (2013) Adesão ao tratamento de doenças crônicas em pediatria: uma revisão crítica da literatura. Rev Med Minas Gerais, 23(2):5-11.
Vaish S., White M., Daly L., Molloy A.M., Staines A., Sweeney M.R. (2016). Synthetic folic acid intakes and status in children living in Ireland exposed to voluntary fortification. Am J Clin Nutr.,103(2):512-518.
Walsh K.E., Cutrona S.L., Kavanagh P.L., Crosby L.E., Malone C., Lobner K., Bundy D.G. (2014). Medication adherence among pediatric patients with sickle cell disease: a systematic review. Pediatrics,134(6):1175-1183.
Ware R.E., de Montalembert M., Tshilolo L., Abboud M.R. (2017). Sickle cell disease. Lancet, 390 (10091):311-323.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Maria Isabel Silva Soares; Yasmin Mazzafera; Tatiana Régia Suzana Amorim Boa Sorte; Gildásio Carvalho da Conceição; Ney Cristian Amaral Boa Sorte
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
